Journal
CLINICAL ONCOLOGY
Volume 25, Issue 2, Pages 109-116Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.clon.2012.10.005
Keywords
Adjuvant; breast; chemotherapy; predictive
Categories
Funding
- NIHR Health Technology Assessment programme
- National Institute for Health Research [CL-2012-02-501, 10/34/01] Funding Source: researchfish
Ask authors/readers for more resources
The mortality from breast cancer has improved steadily over the past two decades, in part because of the increased use of more effective adjuvant therapies. Thousands of women are routinely treated with intensive chemotherapy, which can be unpleasant, is expensive and is occasionally hazardous. Oncologists have long known that some of these women may not need treatment, either because they have a low risk of relapse or because they have tumour biology that makes them less sensitive to chemotherapy and more suitable for early adjuvant endocrine therapy. There is an urgent need to improve patient selection so that chemotherapy is restricted to those patients who will benefit from it. Here we review the emerging technologies that are available for improving patient selection for chemotherapy. We describe the OPTIMA trial, which has just opened to recruitment in the UK, is the latest addition to trials in this area, and is the first to focus on the relative cost-effectiveness of alternate predictive assays. (c) 2012 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available